These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 27029727)

  • 81. Prostate cancer and the role of biomarkers.
    Nevo A; Navaratnam A; Andrews P
    Abdom Radiol (NY); 2020 Jul; 45(7):2120-2132. PubMed ID: 31720770
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Novel Diagnostic Biomarkers of Prostate Cancer: An Update.
    Anceschi U; Tuderti G; Lugnani F; Biava PM; Malossini G; Luciani L; Cai T; Marsiliani D; Filianoti A; Mattevi D; Costantini M; Misuraca L; Simone G
    Curr Med Chem; 2019; 26(6):1045-1058. PubMed ID: 30215331
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.
    Law KW; Nguyen DD; Barkin J; Zorn KC
    Can J Urol; 2020 Feb; 27(27 Suppl 1):3-10. PubMed ID: 32101694
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prevention and early detection of prostate cancer.
    Cuzick J; Thorat MA; Andriole G; Brawley OW; Brown PH; Culig Z; Eeles RA; Ford LG; Hamdy FC; Holmberg L; Ilic D; Key TJ; La Vecchia C; Lilja H; Marberger M; Meyskens FL; Minasian LM; Parker C; Parnes HL; Perner S; Rittenhouse H; Schalken J; Schmid HP; Schmitz-Dräger BJ; Schröder FH; Stenzl A; Tombal B; Wilt TJ; Wolk A
    Lancet Oncol; 2014 Oct; 15(11):e484-92. PubMed ID: 25281467
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The need for active surveillance for low risk prostate cancer.
    Drost FH; Roobol MJ
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):487-489. PubMed ID: 28406334
    [No Abstract]   [Full Text] [Related]  

  • 86. [MOLECULAR MARKERS FOR PROSTATE CANCER].
    Engelstein D
    Harefuah; 2017 May; 156(5):318-321. PubMed ID: 28551905
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials.
    Crawford ED
    Eur Urol; 1999; 35(5-6):511-4. PubMed ID: 10325516
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Smarter screening for prostate cancer.
    Tan GH; Nason G; Ajib K; Woon DTS; Herrera-Caceres J; Alhunaidi O; Perlis N
    World J Urol; 2019 Jun; 37(6):991-999. PubMed ID: 30859272
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Emerging PSA-based tests to improve screening.
    Bryant RJ; Lilja H
    Urol Clin North Am; 2014 May; 41(2):267-76. PubMed ID: 24725489
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [What primary care physicians should know about new markers in prostate cancer].
    Jalón Monzón A; Alvarez Múgica M; Jalón Monzón M; Escaf Barmadah S
    Semergen; 2018 Sep; 44(6):430-438. PubMed ID: 30049576
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prostate Cancer: Update on Early Detection and New Biomarkers.
    Grubb RL
    Mo Med; 2018; 115(2):132-134. PubMed ID: 30228704
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Reconsidering Prostate Cancer Screening.
    Schmidt C
    J Natl Cancer Inst; 2017 Jan; 109(1):1-2. PubMed ID: 28104781
    [No Abstract]   [Full Text] [Related]  

  • 93. [PSA screening 2013: background and perspectives].
    Recker F; Seiler D; Seifert B; Randazzo M; Kwiatkowski M
    Urologe A; 2014 Jun; 53(6):875-81. PubMed ID: 23712424
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer.
    Kumar S; Gurshaney S; Adagunodo Y; Gage E; Qadri S; Sharma M; Malik S; Manne U; Singh UP; Singh R; Mishra MK
    Front Biosci (Landmark Ed); 2018 Jun; 23(11):1987-2000. PubMed ID: 29772540
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Noordzij MA; Blanker MH
    J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
    [No Abstract]   [Full Text] [Related]  

  • 96. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
    Taneja SS
    J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
    [No Abstract]   [Full Text] [Related]  

  • 97. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 98. [Screening for asymptomatic cancers?].
    Jordan B
    Med Sci (Paris); 2018 Apr; 34(4):363-365. PubMed ID: 29658481
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Early detection or screening in the prevention of prostate cancer?].
    Brenes Bermúdez FJ; Alcántara Montero A
    Semergen; 2017 Mar; 43(2):100-108. PubMed ID: 26960257
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prostate-specific antigen as a tumor marker in prostate cancer.
    Kuriyama M
    Int J Urol; 1994 Jun; 1(2):99-113. PubMed ID: 7543013
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.